Custom-Tailored Pharmacokinetics and Pharmacodynamics via Chemical Modifications of Biotech Drugs

Pharmacokinetics and Pharmacodynamics of Biotech Drugs: Principles and Case Studies in Drug Development

Volumn , Issue , 2006, Pages 271-294

  Veronese, Francesco M ^a   Caliceti, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Avidin; Biotech drugs; Chemical aspects; Chemical modifications of biotech drugs; Custom tailored; Drug conjugates; Insulin; Interferons; Non peptide drug conjugation; PEG as drug carrier; Pharmacodynamics; Pharmacokinetics

Indexed keywords

EID: 84889817808     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527609628.ch11     Document Type: Chapter

References (44)

1. Creutzfeldt, W. 2001. The entero-insular axis in type 2 diabetes - incretins as therapeutic agents. Exp. Clin. Endocrinol. Diabetes 109 : 288-303.
2. Lance V.A., W.A. Murphy, J. Sueiras-Diaz, and D.H. Coy. 1984. Super-active analogs of growth hormone-releasing factor (1-29)-amide. Biochem. Biophys. Res. Commun. 119 : 265-272.
3. Brocchini, S., and R. Duncan. 1999. In: Mathiowitz, E. (Ed.), Encyclopedia of Controlled Drug Delivery. Wiley, New York, pp. 786-816.
4. Wong K., L.G. Cleland, and M.J. Poznansky. 1980. Enhanced anti-inflammatory effect and reduced immunogenicity of bovine liver superoxide dismutase by conjugation with homologous albumin. Agents Actions 10 : 231-239.
5. Maeda H., J. Takeshita, and R. Kanamaru. 1979. A lipophilic derivative of neocarzinostatin. A polymer conjugation of an antitumor protein antibiotic. Int. J. Peptide Protein Res. 14 : 81-1487.
6. Caliceti P., O. Schiavon, M. Morpurgo, F.M. Veronese, L. Sartore, E. Ranucci, and P. Ferruti. 1995. Physico-chemical and biological properties of monofunctional hydroxy terminating poly(N-vinylpyrrolidone) conjugated superoxide dismutase. J. Bioact. Comp. Polym. 10 : 103-120.
7. Abuchowski A., J.R. McCoy, N.C. Palczuk, T. van Es, and F.F. Davis. 1977. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalane. Biol. Chem. 252 : 3582-3586.
8. Tochilin V.P., I. Voronkov, and A.V.Mazaev. 1982. Use of immobilized streptokinase (streptodecase) for treating thromboses. Ter. Arkh. 54 :21-25.
9. Kurtzahls P., L. Schaffer, A. Sorensen, C. Kristensen, I. Jonassen, C. Schmid and T. Trub. 2000. Correlation of receptor bind ing and metabolic and mitogenic properties of insulin analogs designed for clinical use. Diabetes 49 : 999-1005.
10. Hashimoto M., K. Takada, Y. Kiso, and S. Muranishi. 1986. Synthesis of palmitoyl derivatives of insulin and their biological activitie. Pharm. Res. 6 : 171-176
11. Jain S., D. H. Hreczuk-Hirst, B. McCormack, M. Mital, A. Epenetos, P. Laing, and G. Gregoriadis. 2003. Polysialylated insulin: synthesis, characterization and biological activity in vivo. Biochim. Biophys. Acta 1622 : 42-49.
12. Chytry V., D. Letourneur, M. Baudys, and J. Jozefonvicz. 1996. Conjugates of insulin with copolymers of N-(2-hydroxypropyl) methacrylamide: effects on smooth muscle cell proliferation. J. Biomed. Mater. Res. 31: 265-272.
13. Von Specht B.U., H.J. Kolb, R. Renner, and K.D. Hepp. 1978. Preparation and physical-chemical characterization of poly-N-vinylpyrrolidone-insuli. Hoppe Seyler's Z. Physiol. Chem. 359 : 231-238
14. Hinds K.D., and S.W. Kim. 2002. Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54 : 505-530.
15. Hinds K., J.J. Koh, L. Joss, F. Liu, M. Baudys, and S.W. Kim. 2000. Synthesis and characterization of poly(ethylene glycol)-insulin conjugates. Bioconjug. Chem. 11: 195-201.
16. Caliceti P., and F.M. Veronese. 1999. Improvement of insulin physico-chemical and biopharmaceutical properties by poly(ethylene glycol) conjugation. J. Drug Deliv. Sci. Technol. 9 : 107-113.
17. Caliceti P., and F.M. Veronese. Successful insulin delivery by PEG conjugation. 25th International Symposium on Controlled Release of Bioactive Materials, June 21-24, 1998, 347.
18. Insulin inhalation - Pfizer/Nektar Therapeutics: HMR 4006, inhaled PEG-insulin - Nektar, PEGylated insulin - Nektar, Drugs RD 2004. 5 : 166-170.
19. Caliceti P., S. Salmaso, G. Walker, and A. Bernkop-Schnürch. 2004. Development and in vivo evaluation of an oral insulin-PEG delivery system. Eur. J. Pharm. Sci. 22 : 315-323.
20. Hinds K. D., K.M. Campbell, K.M. Holland, D. H. Lewis, C. A. Piché, and P. G. Schmidt. 2005. PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J. Control. Release 104 : 447-460.
21. Still G. 2002. Development of oral insulin: progress and current stat. J. Diabetes Metab. Res. Rev. Suppl. 1:S29-S37
22. Rajender Reddy K., M.W. Modi, and S. Pedder. 2002. Use of peginterferon alfa-2 a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54 : 571-586.
23. Bailon P., C.L. Spence, C.A. Schaffer, K. Prinzo, S. Monkrash, J.E. Porter, W.-J. Fung, W.E. DePinto, A. Aglione, L. Stern, G. Truitt, A. Pulleroni, Z.-X. Xu, J. Hoffman, S. Pedder and M. Brunda. 1999. Pharmacokinetic properties of five poly(ethylene glycol) conjugates of interferon alfa-2a. Antivir. Ther. 4 : 27-37.
24. Bailon P., A. Pelleroni, C.A. Schaffer, C.L. Spence, W.-J. Fung, J.E. Porter, G.K. Erlich, W. Pan, Z.-X. Xu., M.W. Modi, A. Farid, and W. Berthold. 2001. Rational design of a potent, long acting form of interferon's 40 kDa branched poly-ethylene glycol conjugated interferon γ 2 a for the treatment of hepatitis C. Bioconjug. Chem. 12 : 1995-2002.
25. Modi M.W., M.W. Fried, R.W. Reindollar, V. R. Rustgi, R. Kenny, T.L. Wright, A. Gibas N.E. Martin, M.L. Shiffman, and L.S. Marsano. 2000. The pharmacokinetic behaviour of pegylated (40 kDa) interferon alfa-2 a (Pegasys) in chronic hepatitis C patients after multiple dosing. Hepatology 32 : 394A.
26. Roisman L.C., J. Piehler, J.Y. Trosset, H.A. Scheraga, and G. Schreiber. 2001. Structure of the interferon-receptor complex determined by distance constraints from double-mutant cycles and flexible docki. Proc. Natl. Acad. Sci. USA 98 : 13231-13236
27. Glue P., J.W. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S.K. Gupta, M. Salfi, and S. Jacobs. 2000. Pegylated interferon-γ2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. Pharmacol. Ther. 68: 556-567.
28. Chinol M., P. Casalini, M. Maggiolo, S. Canevari, E.S. Omodeo, P. Caliceti, F.M. Veronese, M. Cremonesi, F. Chiolerio, E. Nardone, A.G. Siccardi, and G. Paganelli. 1998. Biochemical modifications of avidin improve pharmacokinetics and biodistribution, and reduce immunogenicity. Br. J. Cancer 78 : 189-197.
29. Schechter B., R. Silberman, R. Arnon, and M. Wilchek. 1990. Tissue distribution of avidin and streptavidin injected into mice. Effect of avidin carbohydrate, streptavidin truncation and exogenous biotin. Eur. J. Biochem. 189 : 327-331.
30. Kang Y.S., Y. Saito, and W.M. Pardrige. 1995. Pharmacokinetics of [3H]biotin bound to different avidin analogues. J. Drug Target. 3 : 159-165.
31. Rosebrough S.F., and D.F. Hartley. 1996. Biochemical modification of streptavidin and avidin: in vitro and in vivo analysis. J. Nucleic Med. 37 : 1380-1384.
32. Marttila A.T., O.H. Laitinen, K.J. Airenne, T. Kulik, E.A. Bayer, M. Wilchek, and M.S. Kulomaa. 2000. Recombinant NeutraLite avidin: a non-glycosylated, acidic mutant of chicken avidin that exhibits high affinity for biotin and low non-specific binding properties. FEBS Lett. 467 : 31-36.
33. Caliceti P., M. Chinol, M. Roldo, F.M. Veronese, A. Semenzato, S. Salmaso, and G. Paganelli. 2002. Poly(ethylene glycol)-avidin bioconjugates: suitable candidates for tumor pre-targeting. J. Control. Release 83: 97-108.
34. Caliceti P., M. Chinol, G. Paganelli, S. Salmaso, S. Bersani, and A. Semenzato. 2005. Preparation and characterization of active site protected poly(ethylene glycol) avidin bioconjugates. Biochim. Biophys. Acta 1726 : 57-66.
35. Salmaso S., S. Pennadam, D. Cunliffe, C. Alexander, D. Górecki, and P. Caliceti. Physico-Chemical and Pharmacokinetic Studies of Avidin Bioconjugates with Thermosensitive Polymers, 5th International Symposium on Controlled Release of Bioactive Materials, June 21-24, 1998, 347.
36. Caliceti P., O. Schiavon, F.M. Veronese. 1999. Biopharmaceutical properties of uricase conjugated to neutral amphiphilic polymers, Bioconjug. Chem. 10: 638-646.
37. Duncan R. 2003. The drawing era of polymer therapeutics. Nature Rev. Drug Discov. 2: 347-360
38. Kratz, F., U. Beyer, and M. T. Schutte. 1999. Drug-polymer conjugates containing acid-cleavable bonds carrier system. Crit. Rev. Ther. Drug Carrier Syst. 16, 245-288.
39. Greenwald, R. B., Y. H. Choe, C. D. Conover, K. Shum, D. Wu, and M. Royzen. 2000. Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds. J. Med. Chem. 2000, 43, 475-487.
40. Conover C.D., H. Zhao, C.B. Longley, K.L. Shum, and R.B. Greenwald. 2003. Utility of poly(ethylene glycol) conjugation to create prodrugs of amphotericin B. Bioconjug. Chem. 14 : 661-666.
41. Guiotto A., M. Canevari, M. Pozzobon, S. Moro, P. Orsolini, and F.M. Veronese. 2004. Anchimeric assistance effect on regioselective hydrolysis of branched PEGs: a mechanistic investigation. Bioorg. Med. Chem. 12 : 5031-5037.
42. Conover C.D., R.B. Greenwald, A. Pendri, C.W. Gilbert, and K.L. Shum. 1998. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother. Pharmacol. 42 : 407-414.
43. Schiavon O., G. Pasut, S. Moro, P. Orsolini, A. Guiotto, and F.M. Veronese. 2004. PEG-Ara-C conjugates for controlled release. Eur. J. Med. Chem. 2 : 123-133.
44. Choe Y.H., C.D. Conover, D. Wu, M. Royzen, Y. Gervacio, V. Borowski, M. Mehlig, and R.B. Greenwald. 2002. Anticancer drug delivery systems: multiloaded N4-acyl poly(ethylene glycol) prodrugs of ara-C. II. Efficacy in ascites and solid tumors. J. Control. Release 79 : 55-70.